Abstract
Breast cancer is treated with tamoxifen, an antagonist classified as selective estrogen receptor modulator, widely used for the first-line treatment of breast cancer. Resveratrol, a polyphenol present in the diet, has received attention due to its beneficial biological properties. There is great demand of science for new therapeutic targets for the treatment of breast cancer. Thus, evaluate cellular cytotoxicity of resveratrol, desmethyltamoxifen and their combination by the method MTT assay in culture estrogen-dependent breast cancer cells (MCF -7) and estrogen-independent (MDA-MB -231) will allow assess whether resveratrol provides benefits for the treatment of breast cancer. Our results indicate that the combination of resveratrol with tamoxifen reduced the viability of additive manner in breast cancer cells.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
